Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03451435 · ClinicalTrials.gov registry record · Early Phase 1

N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization

A Early Phase 1 study, sponsored by University of California, Los Angeles.

Terminated
Registry status
Early Phase 1
Development phase
7
Enrollment target

NCT03451435 is a Early Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03451435, a Early Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.

TERMINATED
Registry status
Early Phase 1
Development phase
7 participants
Enrollment target

Study Summary

Pulp re-vascularization/regeneration is a procedure performed to allow pulpal stem cells to survive and/or differentiate to allow immature tooth root structures to grow to full maturity. Currently, the procedure includes disinfection of the necrotic root canal space and induction of bleeding to potentiate pulpal stem cell differentiation to allow root growth on an immature root. A number of studies conducted previously demonstrate that N-acetyl cysteine (NAC) potentiates differentiation of pulpal stem/stromal cells and protects pulpal cells from apoptosis. 14-18 human subjects will be recruited forming two groups where pulp re-vascularization/regeneration procedures will be performed with or without the use of NAC treatment prior to induction of bleeding. Recall follow-up appointments will be done at 6 months and 1 year post treatment with subsequent yearly appointments until full root growth has been achieved.

Interventions

  • DRUG N acetyl cysteine

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2018-06-15
Est. Completion 2019-04-01
Phase Early Phase 1

What the Registry Record Tells You About NCT03451435

The ClinicalTrials.gov registry entry for NCT03451435 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which N acetyl cysteine is the first listed.

NCT03451435 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03451435 about?

NCT03451435 is a clinical study titled "N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization". Pulp re-vascularization/regeneration is a procedure performed to allow pulpal stem cells to survive and/or differentiate to allow immature tooth root structures to grow to full maturity. Currently, the procedure includes disinfection of the necrotic root canal space and induction of bleeding to pote...

What is the current status of trial NCT03451435?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2018-06-15. Estimated completion is 2019-04-01.

What interventions are being tested in trial NCT03451435?

The interventions under investigation include: N acetyl cysteine (DRUG).

Who is sponsoring clinical trial NCT03451435?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.